How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Novel chalcone derivative for cancer treatment

Organization name

Medical University of Vienna

Profile

Background

Researchers of the Medical University of Vienna have identified highly active synthetic chalcones derived from the chalcone scaffold. These cytotoxic compounds were found and developed by modifying the chalcone lead structure concurrent with in vitro tests to evaluate their cytotoxic potential in different cancer cell lines. Compounds were thoroughly tested regarding their efficacy in inhibiting proliferation and viability in cancer cell lines of the hematopoietic system.

Benefits

From these tests, one representative emerged, which inhibits proliferation of CLL cells in vitro at very low concentrations and simultaneously displays less effect on healthy donor cell growth.

The combination of the new chalcone compound with the targeting agents, Idelalisib and Ibrutinib, which are novel compounds in the treatment of hematological malignancies, displayed higher cytotoxicity on CLL cells than Idelalisib and Ibrutinib alone.

Next steps

  • determination of cytotoxity in a pre-clinical experimental system
  • In depth analysis regarding the mode of action

Cooperation options

  • Development partnership
  • License agreement, or other

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries